This company listing is no longer active
2IVA Stock Overview
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Indivior PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£19.30 |
52 Week High | UK£78.00 |
52 Week Low | UK£14.50 |
Beta | -0.031 |
1 Month Change | 11.56% |
3 Month Change | 24.52% |
1 Year Change | 19.88% |
3 Year Change | 297.12% |
5 Year Change | -9.81% |
Change since IPO | 918.47% |
Recent News & Updates
Recent updates
Shareholder Returns
2IVA | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 2.1% | 1.6% |
1Y | 19.9% | -26.3% | 6.4% |
Return vs Industry: 2IVA exceeded the German Pharmaceuticals industry which returned -8.3% over the past year.
Return vs Market: 2IVA exceeded the German Market which returned 0.8% over the past year.
Price Volatility
2IVA volatility | |
---|---|
2IVA Average Weekly Movement | 8.7% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2IVA has not had significant price volatility in the past 3 months.
Volatility Over Time: 2IVA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 1,000 | Mark Crossley | https://www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet.
Indivior PLC Fundamentals Summary
2IVA fundamental statistics | |
---|---|
Market cap | €2.80b |
Earnings (TTM) | -€46.46m |
Revenue (TTM) | €879.95m |
3.2x
P/S Ratio-60.2x
P/E RatioIs 2IVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2IVA income statement (TTM) | |
---|---|
Revenue | US$947.00m |
Cost of Revenue | US$161.00m |
Gross Profit | US$786.00m |
Other Expenses | US$836.00m |
Earnings | -US$50.00m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.36 |
Gross Margin | 83.00% |
Net Profit Margin | -5.28% |
Debt/Equity Ratio | 331.9% |
How did 2IVA perform over the long term?
See historical performance and comparison